Journal for ImmunoTherapy of Cancer (Nov 2020)

401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

  • Marcin Kowanetz,
  • Manish Sharma,
  • Jeeyun Lee,
  • Leisha Emens,
  • Keun-Wook Lee,
  • Yoon-Koo Kang,
  • Paula Pohlmann,
  • Glenn Hanna,
  • Ecaterina Ileana Dumbrava,
  • Daniel Catenacci,
  • Dejan Juric,
  • Bob Li,
  • Kathleen Moore,
  • Mark Pegram,
  • Antoinette Tan,
  • Shelley Ackerman,
  • Heidi LeBlanc,
  • David Dornan,
  • Michael Alonso,
  • Edith Perez

DOI
https://doi.org/10.1136/jitc-2020-SITC2020.0401
Journal volume & issue
Vol. 8, no. Suppl 3

Abstract

Read online

No abstracts available.